Market Research Logo

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2018

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2018

Summary

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes clos


Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development
Adamed Sp z oo
Astellas Pharma Inc
Avineuro Pharmaceuticals Inc
H. Lundbeck AS
Johnson & Johnson
Reviva Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles
ADN-1184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-3662 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDD-028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-18038683 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for Migraine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target 5-HT7R for Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vortioxetine hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones
Featured News & Press Releases
Oct 22, 2018: U.S. Food and Drug Administration approves expansion of Trintellix (vortioxetine) label
Oct 22, 2018: New Data Added to TRINTELLIX (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder
Sep 28, 2018: Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine in Japan for the treatment of Major Depressive Disorder (MDD)
Jun 08, 2018: Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder
May 02, 2018: TRINTELLIX (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)
May 02, 2018: Sunovion to Presents Data on Latuda at the 2018 American Psychiatric Association Annual Meeting
Apr 20, 2018: Sunovion Announces Health Canada Approval of Latuda (lurasidone HCl) to Treat Adolescents (13 to 17 years of age) with Bipolar Depression
Apr 18, 2018: Sumitomo Dainippon Pharma Announces U.S. Appellate Court Decision on Substance Patent Infringement Lawsuit Regarding LATUDA
Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Mar 06, 2018: Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
Feb 23, 2018: Sumitomo Dainippon Pharma Filed Patent Infringement Lawsuits Regarding LATUDA in US
Feb 14, 2018: Sumitomo Dainippon Pharma Filed Patent Infringement Lawsuits Regarding LATUDA in the United States
Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101
Dec 04, 2017: Lundbeck’s Brintellix approved in China
Oct 27, 2017: Sunovion Presents Data from Phase 3 Studies of Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Adamed Sp z oo, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by Avineuro Pharmaceuticals Inc, H2 2018
Pipeline by H. Lundbeck AS, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Reviva Pharmaceuticals Inc, H2 2018
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report